<p>/PRNewswire/ -- Intensity Therapeutics, Inc.（納斯達克代碼：INTS）是一家處於後期臨牀階段的生物技術公司，專注於發現和開發專有的新型免疫基礎腫瘤內治療方法，旨在殺死腫瘤並增強免疫系統對癌症的識別。公司宣佈創始人、總裁兼首席執行官 Lewis H. Bender 將在 H.C. Wainwright 第 26 屆年度全球投資會議上進行公司概述的演講。會議將於 2024 年 9 月 9 日至 11 日在紐約樂天酒店舉行。</p>
<p><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2290007/Intensity_Therapeutics_Inc_Logo.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2290007/Intensity_Therapeutics_Inc_Logo.jpg"/></p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>演講日期：</td>
<td>2024 年 9 月 11 日，星期三</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>時間：</td>
<td>東部時間上午 11:30（Holmes I – 4 樓）</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>網絡直播鏈接：</td>
<td></td>
</tr>
<tr>
<td>https://journey.ct.events/view/ef21791d-dcfa-4af5-a93b-8ba594c598c6</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>
<p>演講的實時網絡直播可以在 Intensity Therapeutics 網站的投資者關係部分訪問。網絡直播的回放將在活動結束後存檔，並可在大約 90 天內觀看。</p>
<p>https://ir.intensitytherapeutics.com/news-events/events-presentations</p>
<p>Bender 先生和首席財務官 Joseph Talamo 將在整個會議期間提供一對一的會議。要請求會議並註冊會議，請點擊以下鏈接：</p>
<p>https://hcwevents.com/annualconference/</p>
<p><strong>關於 Intensity Therapeutics</strong> Intensity Therapeutics 是一家處於後期臨牀階段的生物技術公司，應用新型工程化化學，通過使其含水細胞毒藥物產品 INT230-6 與腫瘤的高脂肪高壓環境混合並飽和。由於飽和，Intensity 的臨牀試驗已證明 INT230-6 能夠在注射後幾天內殺死腫瘤並引發適應性免疫反應，代表了一種新的癌細胞死亡方法，具有改變治療範式的潛力，使許多致命癌症轉變為慢性疾病，即使是對免疫療法無反應的癌症。INT230-6 在兩項研究中已完成超過 200 名患者的入組；一項是 1/2 期劑量遞增試驗（NCT03058289），另一項是針對乳腺癌的 2 期隨機對照臨牀試驗（INVINCIBLE-2 研究）（NCT04781725）。公司還啓動了一項針對軟組織肉瘤的 3 期試驗（INVINCIBLE-3 研究）（NCT06263231），測試 INT230-6 作為第二或第三線單藥治療，與標準治療相比，以總體生存率為終點。公司還計劃在術前三陰性乳腺癌中進行 2/3 期項目，測試 INT230-6 與標準治療聯合使用，與單獨的標準治療相比。該項目的 2 期部分（INVINCIBLE-4 研究）信息列於（NCT06358573）。有關公司的更多信息，包括關於其新型癌症治療方法的出版物、論文和海報，請訪問 www.intensitytherapeutics.com。</p>
<p><strong>前瞻性聲明</strong> 本新聞稿中的某些聲明可能構成 1995 年美國私人證券訴訟改革法案（截至目前的修訂）所定義的 “前瞻性聲明”。這些聲明包括但不限於與公司預期未來計劃、現金流、開發活動、預計里程碑、商業活動或結果相關的聲明。當在本通訊中使用時，諸如 “可能”、“可以”、“應該”、“預期”、“相信”、“估計”、“期望”、“打算”、“計劃”、“預測” 等類似表達及其變體，可能識別出前瞻性聲明。本新聞稿中包含的前瞻性聲明基於管理層對未來事件的當前預期和預測，然而，實際結果或事件可能與披露或暗示的計劃、意圖和期望有實質性差異。這些風險和不確定性中的許多超出了我們的控制，包括：未來的臨牀前研究和臨牀試驗及研發項目的啓動、時間、進展和結果；在公司預計從產品銷售中產生任何收入之前需要籌集額外資金；開發和商業化產品候選者的計劃；監管申請和批准的時間或可能性；公司研究生成和推進額外產品候選者的能力；公司商業模式的實施、公司業務、產品候選者和技術的戰略計劃；商業化、市場營銷和製造能力及戰略；公司系統的市場接受率和臨牀效用的速度和程度；公司的競爭地位；公司的知識產權地位；與公司競爭對手及其行業相關的發展和預測；公司維持和建立合作關係或獲得額外資金的能力；與現金及現金等價物和投資的使用相關的預期；關於費用、未來收入、資本需求和額外融資需求的估計；以及在公司 SEC 文件中描述的其他風險，相關文件可在 SEC 網站 www.sec.gov 上獲取。讀者被警告不要對前瞻性聲明過於依賴，這些聲明僅在作出時有效，並反映管理層的當前估計、預測、期望和信念。公司不計劃更新任何此類前瞻性聲明，並明確拒絕更新本新聞稿中包含的信息，除非法律要求。</p>
<p><strong>投資者關係聯繫人：</strong> Justin Kulik</p>
<p>justin@coreir.com</p>
<p>(558) 230-6401</p>
<p><strong>媒體聯繫人：</strong> Jules Abraham</p>
<p>CORE IR</p>
<p>julesa@coreir.com</p>
<p>來源：Intensity Therapeutics Inc.</p>

INTS

<p>Intensity Therapeutics, Inc.（納斯達克代碼：INTS）將在 2024 年 9 月 11 日的 H.C. Wainwright 第 26 屆年度全球投資會議上進行公司概述。首席執行官 Lewis H. Bender 和首席財務官 Joseph Talamo 將會進行一對一的會議。該公司專注於開發基於免疫的癌症療法，其藥物 INT230-6 在多種癌症的臨牀試驗中顯示出良好的前景。公告中包含了關於未來計劃和風險的前瞻性聲明。有關更多詳細信息，請訪問他們網站的投資者關係部分</p>

<p>, /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, announces that Lewis H. Bender, Founder, President and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 26th Annual Global Investment Conference. The conference is being held on September 9 – 11, 2024 at the Lotte New York Palace Hotel.</p>
<div class="lb-trans"><p>/PRNewswire/ -- Intensity Therapeutics, Inc.（納斯達克代碼：INTS）是一家處於後期臨牀階段的生物技術公司，專注於發現和開發專有的新型免疫基礎腫瘤內治療方法，旨在殺死腫瘤並增強免疫系統對癌症的識別。公司宣佈創始人、總裁兼首席執行官 Lewis H. Bender 將在 H.C. Wainwright 第 26 屆年度全球投資會議上進行公司概述的演講。會議將於 2024 年 9 月 9 日至 11 日在紐約樂天酒店舉行。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2290007/Intensity_Therapeutics_Inc_Logo.jpg" alt="" original-src="https://mma.prnewswire.com/media/2290007/Intensity_Therapeutics_Inc_Logo.jpg"/></p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Presentation Date:</td>
<td>Wednesday, September 11, 2024</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Time:</td>
<td>11:30 AM ET (Holmes I – 4th Floor)</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Webcast Link:<br/>https://journey.ct.events/view/ef21791d-dcfa-4af5-a93b-8ba594c598c6</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>演講日期：</td>
<td>2024 年 9 月 11 日，星期三</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>時間：</td>
<td>東部時間上午 11:30（Holmes I – 4 樓）</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>網絡直播鏈接：</td>
<td></td>
</tr>
<tr>
<td>https://journey.ct.events/view/ef21791d-dcfa-4af5-a93b-8ba594c598c6</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>
</div><p>A live webcast of the presentation can be accessed on the investor relations section of the Intensity Therapeutics website. A replay of the webcast will be archived and available following the event for approximately 90 days.</p>
<div class="lb-trans"><p>演講的實時網絡直播可以在 Intensity Therapeutics 網站的投資者關係部分訪問。網絡直播的回放將在活動結束後存檔，並可在大約 90 天內觀看。</p>
</div><p>https://ir.intensitytherapeutics.com/news-events/events-presentations</p>
<div class="lb-trans"><p>https://ir.intensitytherapeutics.com/news-events/events-presentations</p>
</div><p>Mr. Bender and Joseph Talamo, Chief Financial Officer, will be available for one-on-one meetings throughout the conference. To request a meeting and to register for the conference, please click below:</p>
<div class="lb-trans"><p>Bender 先生和首席財務官 Joseph Talamo 將在整個會議期間提供一對一的會議。要請求會議並註冊會議，請點擊以下鏈接：</p>
</div><p>https://hcwevents.com/annualconference/</p>
<div class="lb-trans"><p>https://hcwevents.com/annualconference/</p>
</div><p><strong>About Intensity Therapeutics</strong> Intensity Therapeutics is a late-stage clinical biotechnology company that applies novel engineered chemistry by enabling its aqueous cytotoxic-containing drug product, INT230-6, to mix and saturate the dense, high-fat pressurized environment of the tumor. As a result of the saturation, Intensity's clinical trials have demonstrated the ability of INT230-6 to kill tumors and elicit an adaptive immune response within days of injection, representing a novel approach to cancer cell death that holds the potential to shift the treatment paradigm and turn many deadly cancers into chronic diseases even for cancers that do not respond to immunotherapy. INT230-6 has completed enrollment of over 200 patients in two studies; a Phase 1/2 dose escalation trial (NCT03058289), and a Phase 2 randomized control clinical trial in breast cancer (the INVINCIBLE-2 study) (NCT04781725). The Company initiated a Phase 3 trial in soft tissue sarcoma (the INVINCIBLE-3 study) (NCT06263231), testing INT230-6 as second or third line monotherapy compared to the standard of care with overall survival as an endpoint. The Company is also planning a Phase 2/3 program in presurgical triple negative breast cancer testing INT230-6 in combination with standard of care compared to standard of care alone. Information on the Phase 2 portion of the program (INVINCIBLE-4 Study) is listed under (NCT06358573). For more information about the Company, including publications, papers and posters about its novel approach to cancer therapeutics, visit www.intensitytherapeutics.com.</p>
<div class="lb-trans"><p><strong>關於 Intensity Therapeutics</strong> Intensity Therapeutics 是一家處於後期臨牀階段的生物技術公司，應用新型工程化化學，通過使其含水細胞毒藥物產品 INT230-6 與腫瘤的高脂肪高壓環境混合並飽和。由於飽和，Intensity 的臨牀試驗已證明 INT230-6 能夠在注射後幾天內殺死腫瘤並引發適應性免疫反應，代表了一種新的癌細胞死亡方法，具有改變治療範式的潛力，使許多致命癌症轉變為慢性疾病，即使是對免疫療法無反應的癌症。INT230-6 在兩項研究中已完成超過 200 名患者的入組；一項是 1/2 期劑量遞增試驗（NCT03058289），另一項是針對乳腺癌的 2 期隨機對照臨牀試驗（INVINCIBLE-2 研究）（NCT04781725）。公司還啓動了一項針對軟組織肉瘤的 3 期試驗（INVINCIBLE-3 研究）（NCT06263231），測試 INT230-6 作為第二或第三線單藥治療，與標準治療相比，以總體生存率為終點。公司還計劃在術前三陰性乳腺癌中進行 2/3 期項目，測試 INT230-6 與標準治療聯合使用，與單獨的標準治療相比。該項目的 2 期部分（INVINCIBLE-4 研究）信息列於（NCT06358573）。有關公司的更多信息，包括關於其新型癌症治療方法的出版物、論文和海報，請訪問 www.intensitytherapeutics.com。</p>
</div><p><strong>Forward-Looking Statements</strong> Certain statements in this press release may constitute &#34;forward-looking statements&#34; within the meaning of the United States Private Securities Litigation Reform Act of 1995, as amended to date. These statements include, but are not limited to, statements relating to the Company's expected future plans, cash runway, development activities, projected milestones, business activities or results. When or if used in this communication, the words &#34;may,&#34; &#34;could,&#34; &#34;should,&#34; &#34;anticipate,&#34; &#34;believe,&#34; &#34;estimate,&#34; &#34;expect,&#34; &#34;intend,&#34; &#34;plan,&#34; &#34;predict&#34; and similar expressions and their variants, as they relate to the Company or its management, may identify forward-looking statements. The forward-looking statements contained in this press release are based on management's current expectations and projections about future events, nevertheless, actual results or events could differ materially from the plans, intentions and expectations disclosed in, or implied by, the forward-looking statements. These risks and uncertainties, many of which are beyond our control, include: the initiation, timing, progress and results of future preclinical studies and clinical trials and research and development programs; the need to raise additional funding before the Company can expect to generate any revenues from product sales; plans to develop and commercialize product candidates; the timing or likelihood of regulatory filings and approvals; the ability of the Company's research to generate and advance additional product candidates; the implementation of the Company's business model, strategic plans for the Company's business, product candidates and technology; commercialization, marketing and manufacturing capabilities and strategy; the rate and degree of market acceptance and clinical utility of the Company's system; the Company's competitive position; the Company's intellectual property position; developments and projections relating to the Company's competitors and its industry; the Company's ability to maintain and establish collaborations or obtain additional funding; expectations related to the use of cash and cash equivalents and investments; estimates regarding expenses, future revenue, capital requirements and needs for additional financing; and other risks described in the section entitled &#34;Risk Factors&#34; in the Company's SEC filings, which can be obtained on the SEC website at www.sec.gov. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management's current estimates, projections, expectations and beliefs. The Company does not plan to update any such forward-looking statements and expressly disclaims any duty to update the information contained in this press release except as required by law.</p>
<div class="lb-trans"><p><strong>前瞻性聲明</strong> 本新聞稿中的某些聲明可能構成 1995 年美國私人證券訴訟改革法案（截至目前的修訂）所定義的 “前瞻性聲明”。這些聲明包括但不限於與公司預期未來計劃、現金流、開發活動、預計里程碑、商業活動或結果相關的聲明。當在本通訊中使用時，諸如 “可能”、“可以”、“應該”、“預期”、“相信”、“估計”、“期望”、“打算”、“計劃”、“預測” 等類似表達及其變體，可能識別出前瞻性聲明。本新聞稿中包含的前瞻性聲明基於管理層對未來事件的當前預期和預測，然而，實際結果或事件可能與披露或暗示的計劃、意圖和期望有實質性差異。這些風險和不確定性中的許多超出了我們的控制，包括：未來的臨牀前研究和臨牀試驗及研發項目的啓動、時間、進展和結果；在公司預計從產品銷售中產生任何收入之前需要籌集額外資金；開發和商業化產品候選者的計劃；監管申請和批准的時間或可能性；公司研究生成和推進額外產品候選者的能力；公司商業模式的實施、公司業務、產品候選者和技術的戰略計劃；商業化、市場營銷和製造能力及戰略；公司系統的市場接受率和臨牀效用的速度和程度；公司的競爭地位；公司的知識產權地位；與公司競爭對手及其行業相關的發展和預測；公司維持和建立合作關係或獲得額外資金的能力；與現金及現金等價物和投資的使用相關的預期；關於費用、未來收入、資本需求和額外融資需求的估計；以及在公司 SEC 文件中描述的其他風險，相關文件可在 SEC 網站 www.sec.gov 上獲取。讀者被警告不要對前瞻性聲明過於依賴，這些聲明僅在作出時有效，並反映管理層的當前估計、預測、期望和信念。公司不計劃更新任何此類前瞻性聲明，並明確拒絕更新本新聞稿中包含的信息，除非法律要求。</p>
</div><p><strong>Investor Relations Contact:</strong> Justin Kulik</p>
<div class="lb-trans"><p><strong>投資者關係聯繫人：</strong> Justin Kulik</p>
</div><p>justin@coreir.com</p>
<div class="lb-trans"><p>justin@coreir.com</p>
</div><p>(558) 230-6401</p>
<div class="lb-trans"><p>(558) 230-6401</p>
</div><p><strong>Media Contact:</strong> Jules Abraham</p>
<div class="lb-trans"><p><strong>媒體聯繫人：</strong> Jules Abraham</p>
</div><p>CORE IR</p>
<div class="lb-trans"><p>CORE IR</p>
</div><p>julesa@coreir.com</p>
<div class="lb-trans"><p>julesa@coreir.com</p>
</div><p>SOURCE Intensity Therapeutics Inc.</p>
<div class="lb-trans"><p>來源：Intensity Therapeutics Inc.</p>
</div>

Saia 宣佈品牌整合 | SAIA 股票新聞